Fuse Diagnostics secures £560.9k for rapid testing platforms

Ultra-rapid diagnostic products are the focus of Fuse Diagnostics Limited, which has just secured an estimated £560.9k in new funding. Based in Saint Ives, the biotechnology company develops platforms including FUSE, FLIP, and APEX to provide laboratory-quality results at the point of need for various industries. The technology is applied to areas such as COVID-19 detection.

The firm was incorporated in 2022 to address performance and cost challenges associated with traditional immunoassay and PCR technologies. By utilizing multianalytic chemistry and product innovations, it seeks to decentralize testing. These low-cost solutions are intended to make diagnostics accessible outside of traditional laboratory settings.

This latest capital injection follows a total of £439.1k raised during 2025. According to accounts for the year ended 31 December 2024, the organization employed 10 people, though LinkedIn data suggests the headcount has since reached 12. The business maintains a presence in Cambridge, operates within the manufacturing sector, and completed the allotment of these new shares in June 2026.